Celyad SA (CYAD.BR)
13 Dec 2017
Fri, Nov 17 2017
* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL
* Celyad SA files for mixed shelf offering of up to $250 million - SEC filing Source text: [http://bit.ly/2xBg9Sn] Further company coverage:
* H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO
* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers
* PUBLISHES ADDITIONAL PRE-CLINICAL DATA IN SUPPORT OF THINK TRIAL
- Celyad: Why Did It Go Down Recently?
- Will Biotech Continue To Boom?
- 3 Things In Biotech You Should Learn Today: October 4, 2017
- Celyad: Some Questions For Management
- Gilead And CAR-T Of Solid Tumors: The Next Revolution In Cancer Therapeutics
- Buy Celyad And Get In On The CAR-T Space In Solid Tumors: Medicine's Next Frontier